Skip to main content
. Author manuscript; available in PMC: 2013 Mar 6.
Published in final edited form as: Nat Struct Mol Biol. 2011 Nov 6;18(12):1336–1344. doi: 10.1038/nsmb.2142

Figure 7. Combination therapeutic effects of low dose of TAT-vif1 and TAT-vif2 peptides.

Figure 7

(a) BCBL-1 cells were treated with 25 µM of each peptide, alone or in combination, for the indicated time periods. Cells were examined by trypan blue staining for cell death analysis or cell number counting for cell growth. *P < 0.05 and ** P < 0.01. (b) BCBL-1 cells were incubated for 6 h with 25 µM of TAT-vif1, TAT-vif2, or both. WCL were subjected to SDS-PAGE followed by IB and were analyzed for p53, MDM2, p21, and HAUSP expression. (c) Asynchronously growing BCBL-1 cells were treated with 25 µM of the designated peptide or combined for the indicated time periods. Cells were pulse-labeled with BrdU and analyzed for DNA content by flow cytometry. BrdU incorporation during the S phase is indicated as the percentage of stained cells. (d) Scatter plot of Annexin V-FITC/PI flow cytometry of BCBL-1 cells after exposure to 25 µM peptide treatments for different time periods. Data are representative of three independent experiments. (e) After tumors were established in the NOD/SCID mice, 0.25 mg each of TAT-vif1 and TAT-vif2 peptide were injected together for 2 weeks. The tumors were measured by in vivo bioluminescence imaging.